Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A...
Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity
About this item
Full title
Author / Creator
Publisher
Switzerland: Frontiers Research Foundation
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: Frontiers Research Foundation
Subjects
More information
Scope and Contents
Contents
Major depressive disorder (MDD) is the most prevalent mental illness contributing to global disease burden. Selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the first-line treatment for MDD, but are only fully effective in 30% of patients and require weeks before improvement may be seen. About 30% of SSRI-resistant patients may respond to...
Alternative Titles
Full title
Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_fe0bb8c0a37e433dac521af061708bb7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_fe0bb8c0a37e433dac521af061708bb7
Other Identifiers
ISSN
1662-453X,1662-4548
E-ISSN
1662-453X
DOI
10.3389/fnins.2019.00404
